Strain-Level Screening of Human Gut Microbes Identifies Three Lactobacillus Strains as Next-Generation Antidiabetic Probiotics

IF 7.4 Q1 FOOD SCIENCE & TECHNOLOGY
Food frontiers Pub Date : 2024-12-11 DOI:10.1002/fft2.523
Yanan Yang, Mingxi Li, Fang Zhang, Jiaqi Yu, Jiale Cheng, Wenyi Xu, Chongming Wu
{"title":"Strain-Level Screening of Human Gut Microbes Identifies Three Lactobacillus Strains as Next-Generation Antidiabetic Probiotics","authors":"Yanan Yang,&nbsp;Mingxi Li,&nbsp;Fang Zhang,&nbsp;Jiaqi Yu,&nbsp;Jiale Cheng,&nbsp;Wenyi Xu,&nbsp;Chongming Wu","doi":"10.1002/fft2.523","DOIUrl":null,"url":null,"abstract":"<p>Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia. Probiotic supplementation improves glucolipid metabolism by modulating the gut microbiota. However, current research lacks a systematic understanding of the overall hypoglycemic ability of human gut microbes. First, a high-throughput screening platform based on HepG2 cells was developed to screen candidate strains with hypoglycemic potential. Subsequently, we utilized a T2DM mouse model to investigate the antidiabetic effects and mechanisms of three selected <i>Lactobacillus</i> strains through biochemical analyses, histopathological analyses, RNA-seq analyses, and metagenomics analyses. We categorized and ranked the hypoglycemic ability of 4811 strains belonging to 8 phyla, 17 orders, 68 genera, and 241 species. The hypoglycemic ability of all tested strains showed a significant normal distribution, and several species with significant efficacy were screened, primarily from <i>Bifidobacterium</i> and <i>Lactobacillus</i>. Subsequently, we found that three <i>Lactobacillus</i> strains significantly improve glycolipid metabolism disorders in T2DM mice, and the mechanisms include inhibiting hepatic gluconeogenesis via the AKT–FOXO1–PEPCK/G6pase pathway and activating GPR41 and GPR43 to bind short-chain fatty acids, promoting glucagon-like peptide-1 (GLP-1) secretion. These strains also significantly regulate the gut microbiota structure and composition, contributing to their hypoglycemic effects. This study comprehensively examined the hypoglycemic efficacy of 4811 strains for the first time, resulting in a functional map of human gut microbiota for hypoglycemia. Additionally, we investigated the hypoglycemic efficacy and the mechanisms of three <i>Lactobacillus</i> strains. This study provides a rich bacterial pool for the targeted development of probiotics as potential treatments for diabetes and related metabolic diseases.</p>","PeriodicalId":73042,"journal":{"name":"Food frontiers","volume":"6 2","pages":"1041-1057"},"PeriodicalIF":7.4000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/fft2.523","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food frontiers","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fft2.523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia. Probiotic supplementation improves glucolipid metabolism by modulating the gut microbiota. However, current research lacks a systematic understanding of the overall hypoglycemic ability of human gut microbes. First, a high-throughput screening platform based on HepG2 cells was developed to screen candidate strains with hypoglycemic potential. Subsequently, we utilized a T2DM mouse model to investigate the antidiabetic effects and mechanisms of three selected Lactobacillus strains through biochemical analyses, histopathological analyses, RNA-seq analyses, and metagenomics analyses. We categorized and ranked the hypoglycemic ability of 4811 strains belonging to 8 phyla, 17 orders, 68 genera, and 241 species. The hypoglycemic ability of all tested strains showed a significant normal distribution, and several species with significant efficacy were screened, primarily from Bifidobacterium and Lactobacillus. Subsequently, we found that three Lactobacillus strains significantly improve glycolipid metabolism disorders in T2DM mice, and the mechanisms include inhibiting hepatic gluconeogenesis via the AKT–FOXO1–PEPCK/G6pase pathway and activating GPR41 and GPR43 to bind short-chain fatty acids, promoting glucagon-like peptide-1 (GLP-1) secretion. These strains also significantly regulate the gut microbiota structure and composition, contributing to their hypoglycemic effects. This study comprehensively examined the hypoglycemic efficacy of 4811 strains for the first time, resulting in a functional map of human gut microbiota for hypoglycemia. Additionally, we investigated the hypoglycemic efficacy and the mechanisms of three Lactobacillus strains. This study provides a rich bacterial pool for the targeted development of probiotics as potential treatments for diabetes and related metabolic diseases.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.50
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信